rupture, plaque erosion, and calcific nodules, is common among patients with MINOCA and can trigger thrombus formation that leads to MI via distal embolization, superimposed vasospasm, and transient complete thrombosis with spontaneous thrombolysis. Coronary artery vasospasm, another potential cause of MINOCA, defined as marked (ie, >90%) constriction of an epicardial coronary artery with diminished myocardial blood flow, may occur either in response to drugs or toxins or spontaneously caused by abnormal coronary vasomotor tone. Although coronary microvascular dysfunction typically presents as stable ischemic heart disease, 4 it is also considered a potential cause of MINOCA. 2 Microvascular dysfunction can be a cause of ischemia but can also be an effect of myocardial injury of either ischemic or nonischemic origin. 5 The precise contribu- Although the treatment of MI with obstructive coronary artery disease is well established, there is a paucity of randomized data on the effectiveness of preventative therapies for individuals with MINOCA. In this issue of the Journal of the American Heart Association (JAHA), Choo et al 7 analyzed
factors related to all-cause death in MINOCA using a nationwide, multicenter, and prospective registry. They report that patients with MINOCA and those with MI related to obstructive coronary artery disease had comparable clinical outcomes. They also report that the use of renin-angiotensin system blockers and statins was associated with lower mortality in patients with MINOCA. These results appear concordant with the stratified propensity analysis of 9138 patients with MINOCA enrolled in the SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapy) registry, which reported that after a mean follow-up of 4.1 years, there was a significantly lower rate of all-cause mortality, hospitalization for MI, ischemic stroke, and heart failure associated with the use of statins (hazard ratio, 0.77
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[95% CI, 0. 9 and reported that this strategy of vasoreactivity testing to guide treatment is feasible and improves angina in patients with nonobstructive coronary artery disease. This study had several limitations, including using binary cutoffs for the vasoreactivity study, potential bias in symptom ascertainment because the patient and cardiologist were not blinded to group allocation, and potential selection bias in patient enrollment because a considerable proportion of patients undergoing invasive coronary angiography were not enrolled, primarily because of patient preference. Given these limitations, additional studies are indicated to validate these results and the role of vasoreactivity testing among those presenting with MINOCA. While we await the results of MINOCA BAT and other randomized studies, on the basis of available data and the scientific statement from the American Heart Association on MINOCA, 2 we suggest an individualized approach to the management of patients with MINOCA on the basis of the underlying cause (Figure) . The central principle in the management of MINOCA is to elucidate or identify the underlying mechanism for targeted therapies and optimize outcomes. In general, ACEI or ARB and statins should be considered for most patients with MINOCA.
The prognosis of patients with MINOCA depends on the underlying cause, but overall it is not a benign condition, as Figure. Individualized approach to the management of patients with myocardial infarction (MI) with nonobstructive coronary arteries on the basis of the underlying cause. *Additional investigations that may be considered in addition to routine evaluation for patients with acute MI and nonobstructive (<50%) coronary artery stenosis. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CCB, calcium channel blocker; IVUS, intravascular ultrasound; MINOCA, MI in the absence of obstructive coronary artery disease; OCT, optical coherence tomography. reported in the current study by Choo et al 7 10 Additional studies are indicated to assess the optimal therapies for patients presenting with MINOCA, focusing on hard clinical end points, such as mortality and reinfarction. In addition to the hard cardiovascular end points, the impact of MINOCA on quality of health also needs to be evaluated on parameters such as persistent angina, activities of daily living, and depression. 11 For now, on the basis of limited data, it seems reasonable to administer ACEIs/ARBs, statins, and antiplatelet agents to most patients presenting with MINOCA while we await more robust prospective randomized data.
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